## JBL: Jabil Inc. - XLK: Technology

### Executive Summary

VALUE thesis: PEG 0.91 indicates fundamental undervaluation. Quality metrics strong (ROE 40%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($212.63)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Jabil Opens Catheter Development Lab**
- Source: PlasticsToday | 20251209T180818 | Bullish | Relevance: 99%
-  Jabil has opened a new Advanced Catheter Development Lab at its St. Petersburg, FL, headquarters to expand its capabilities in minimally invasive medical device technology. The lab will support universities and major healthcare brands in advancing catheter development and will focus on engineering, prototyping, and new product introduction for advanced catheters and other devices. This initiative reflects Jabil's commitment to investments in medical advances that lead to better outcomes for patients.

**2. Jabil opens Advanced Catheter Development Lab at Florida HQ**
- Source: Medical Design & Outsourcing | 20251208T210818 | Bullish | Relevance: 98%
-  Jabil has launched its new Advanced Catheter Development Lab at its St. Petersburg, Florida headquarters. This facility, part of the Jabil Innovation Center, focuses on advancing minimally invasive medical device technology, particularly for catheters, through engineering, prototyping, and new product introduction. Jabil will collaborate with the University of Florida and University of South Florida faculty to integrate real-world operating room experiences into next-generation medtech development.

**3. Has Jabil’s 469.9% Five Year Surge Left Any Value on the Table in 2025?**
- Source: Simply Wall Street | 20251209T000815 | Somewhat-Bullish | Relevance: 98%
- Jabil (NYSE: JBL) has seen significant growth, up 469.9% over five years, leading investors to question its current valuation at around $225. A Discounted Cash Flow analysis suggests it's undervalued by 12.8% at $258.47 per share, while its Price-to-Earnings ratio of 36.7x, compared to a calculated 'Fair Ratio' of 31.2x, indicates it might be somewhat overvalued based on its fundamentals. The article suggests using "Narratives" for a personalized valuation, incorporating individual beliefs about the company's future performance.

**4. Has Jabil’s 469.9% Five Year Surge Left Any Value on the Table in 2025?**
- Source: Simply Wall Street | 20251209T210818 | Somewhat-Bullish | Relevance: 98%
-  This article analyzes whether Jabil, trading at around $225 after a significant five-year surge, still offers value. Using discounted cash flow (DCF) analysis, the stock appears modestly undervalued, suggesting a 12.8% discount to its estimated fair value. However, a review of its Price to Earnings (PE) ratio suggests it might be overvalued compared to its tailored Fair Ratio.

**5. CLS Stock Surges 260% in a Year: Can It Sustain This Growth Pace?**
- Source: TradingView | 20251208T160924 | Somewhat-Bullish | Relevance: 62%
-  Celestica Inc. (CLS) shares have surged 259.6% over the past year, significantly outperforming the industry, driven by strong demand for AI/ML compute and networking products from hyperscale customers. The company is actively expanding its offerings through new product launches, such as the SD6300 storage platform and new 1.6TbE data center switches, and has diversified its customer base across multiple industries. With positive earnings estimate revisions, a raised 2025 guidance, and a Zacks Rank #1 (Strong Buy), Celestica appears well-positioned for continued growth.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($0.00M) |
| Sells | 50 ($12.50M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.3% (-0.1%)
- Blackrock Inc.: 9.0% (+2.1%)
- Texas Yale Capital C: 6.0% (-0.1%)
- State Street Corpora: 4.9% (+0.7%)
- Wellington Managemen: 4.1% (-30.7%)

### Key Risks

1. Heavy insider selling: $13M sold (50 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +5.7% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.91 indicates undervaluation relative to growth. Quality metrics strong (ROE 40%). Insider selling cluster ($12.5M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $24.5B |
| Beta | 1.26 |
| 52W Range | $108.66 - $237.14 |
| Short Interest | 4.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.91 |
| Forward P/E | 17.7 |
| Current P/E | 20.5 |
| YoY Growth | 16.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 1.6% to 7.3% (+5.7% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 89th percentile. MRS_5 at 2.9% confirms short-term momentum alignment. AM_20 at 9.5% shows strong absolute momentum above own 20MA. Outperforming sector by 6.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (2.85), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 7.26% (CS: 90) | Strong |
| RSI_14 | 67.8 | Neutral |
| MACD Histogram | 2.85 | Bullish |
| vs SMA20 | 1.095x | Above |
| vs SMA50 | 1.090x | Above |
| vs SMA200 | 1.207x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $228.09
- **Stop Loss:** $212.63 (6.8% risk)
- **Target:** $259.01 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 77
- **Position Value:** $17,562.93
- **Portfolio %:** 17.56%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2025-12-17 (Est: $2.72)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.95 | $3.29 | +11.7% |
| 2025Q2 | $2.32 | $2.55 | +9.8% |
| 2025Q1 | $1.83 | $1.94 | +6.2% |
| 2024Q4 | $1.88 | $2.00 | +6.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*